ALK and lung carcinoma: In addition, in a phase II nonrandomized study of the heat shock protein 90 (HSP-90) inhibitor, IPI-504, in patients with advanced lung cancer who previously progressed on EGFR TKI therapy, tumors from 3 patients were retrospectively found to have ALK rearrangements.